In the ever-evolving field of diabetes management, glucagon-like peptide-1 receptor agonists have emerged as a transformative therapeutic class. Among these, retaglutide, retatrutide, and trizepatide represent novel https://safaxtgd748523.howeweb.com/39784419/novel-glp-1-receptor-agonists-retaglutide-retatrutide-and-trizepatide